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1. Introduction 
Hepcidin, a small cystein-rech peptide produced by the liver, was first described as an 
antimicrobial peptide (hepatic bactericidal protein) (Park et al. 2001) and subsequently 
discovered as a key regulator of iron homeostasis. Via regulation of ferroportin, hepcidin 
inhibits intestinal iron absorption and iron release from macrophages and hepatocytes 
(Ganz, 2006; Papanikolaou et al., 2005).  
Hepcidin levels are regulated by at least three independent mechanisms (Nicolas et al., 
2002). Whereas both inflammation and iron loading induce hepcidin production, 
erythropoietic activity suppresses its production. Apart from those factors also endoplasmic 
reticulum stress can induce hepcidin expression (Vecchi et al., 2009). In general, the decrease 
of hepcidin due to the iron deficiency or enhanced erythropoiesis stimulates iron intestinal 
absorption. On the other hand, iron-stimulated hepcidin production prevents iron overload. 
Increase in hepcidin concentration due to inflammation is considered important for iron 
sequestration (Ganz & Nemeth, 2009). Studies of humans with severe inflammatory diseases 
have shown increased levels of hepcidin, suggesting that elevated hepcidin levels play a role 
in the anemia of inflammation (Nemeth et al., 2004; Krijt et al., 2009). Due to dominant 
regulation by interleukin-6 (IL-6), hepcidin was classified as a type II acute-phase protein 
(Nemeth et al., 2003). Increased IL-6 levels cause the binding of signal transducer and 
activator of transcription 3 (STAT3) to the hepcidin promoter, increasing its activity 
(Wrighting & Andrews, 2006). Moreover, hepcidin itself has the potential to bind bivalent 
metal ions (Tselepis et al., 2010) and to mediate transcriptional changes of a wide variety of 
genes which can play important role in inflammatory response (De Domenico et al., 2010). 
That is why hepcidin can be considered as important inflammatory mediator, and its 
measurement can be helpful in many clinical situations. Technical problems prevented 
reliable and routine measurements of active 25 amino acid (aa) hepcidin in plasma until 
2009. Therefore there are only limited data on hepcidin in human subjects, and much of 
findings come from animal and in vitro models. 
To evaluate the time course of plasma hepcidin and its precursor prohepcidin in relation to 
inflammatory parameters, authors used a specific group of patients undergoing large 
cardiac surgery - pulmonary endarterectomy (PEA) in a deep hypothermic circulatory arrest 
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(DHCA). PEA is a potential curative treatment method for patients with chronic 
thromboembolic pulmonary hypertension (CTEPH). PEA provides a significant survival 
advantage, compared to the natural prognosis of CTEPH (Roscoe & Klein, 2008). The 
kinetics of main pro-inflammatory cytokines after PEA were described by Lindner et al. 
(2009) and Maruna et al. (2011) showing the relations of cytokine network to hemodynamic 
disturbances post-surgery. PEA leads to a more pronounced activation of cytokines than 
other surgical procedures (Langer et al., 2004; Martínes-Rosaz, 2006; Maruna et al., 2008 and 
2009) with subsequent development of the systemic inflammatory response syndrome. 
Authors postulated that post-surgery changes of plasma hepcidin and its precursor would 
be responding to dynamics of other acute-phase proteins and related to IL-6 or other main 
inflammatory cytokines development. 
2. Material and methods 
2.1 Patients' group 
A prospective study was approved by local research and ethics committee and a written 
informed consent was obtained from the subjects. Patients with CTEPH scheduled for 
isolated PEA on the 2nd Department of Surgery - Department of Cardiovascular Surgery, 
General Faculty Hospital in Prague were enrolled into study between January 2008 and 
March 2011. Respecting gender differences in hepcidin basal concentrations with 
significantly higher levels in men (Grebenchtchikov et al., 2009), only male patients were 
included into our study. Exclusion criteria were the combination of PEA with other surgical 
procedure (PEA with maze or PEA with coronary artery bypass grafting), postoperative 
bleeding, thromboembolic complication, local and systemic infection, defined according to 
guidelines of the Center for Disease Control and Prevention (Horan & Gaynes, 2004). 
2.2 Anesthesia and surgical procedures 
30 minutes before skin incision, the first prophylactic dose of sultamicillin 1.5 g (Unasyn, 
Pfizer, Italy) was given. The same dose was repeated every 3 hours throughout the 
procedure and every 6 hours postoperatively until postoperative day 2. A total intravenous 
anesthesia using combination of benzodiazepines, propofol, opioids and muscle relaxants 
routinely used in our institution for PEA was given to all study patients. 
The standard approach for PEA was median sternotomy. Cardiopulmonary bypass (CPB) 
was established with cannulation of the ascending aorta and the inferior and superior vena 
cava. DHCA (18 – 20 0C) was used to ensure optimum operating conditions and facilitate 
accurate endarterectomty. Endarterectomy was started with dissection in right level of 
pulmonary artery and followed to the segmental branches. To achieve accurate visualization 
during peripheral dissection, repeated periods of DHCA limited to 20 minutes were 
performed with reestablishment of CPB between them. Arteriotomy on the main pulmonary 
artery was started on the left side and continued to the left branch. After completion of 
endarterectomy on the both sides, CPB was recommenced along with controlled rewarming. 
Weaning from CPB was started with pressure control ventilation with positive end-
expiratory pressure, atrio-ventricular epicardial stimulation, stepwise increased filling of the 
right heart and reduction of pump flow together with low doses of norepinephrine 
Dobutamine (Dobutrex, Lily, Germany) was administered only if inotropic support was 
needed during or after weaning of CPB. Before the end of CPB, we used an ultra filtration 
for hemoconcentration. 
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2.3 Monitoring 
Radial and femoral artery cannulae, triple lumen central venous cannula, Swan-Ganz 
catheter, and single lumen jugular bulb catheter were inserted for continuous monitoring of 
hemodynamic parameters and jugular bulb blood saturation. Left atrial catheter was 
surgically placed for both measurement and norepinephrine administration. 
2.4 Blood sample collection 
Arterial blood samples were drawn from femoral artery catheter before operation, after 
sternotomy, after DHCA, after separation from CPB, then 12, 18, 24, 36, 48, 72, and 120 h 
after separation from CPB. For all measurements, 5-ml of arterial blood was drawn into a 
vacutainer heparin tube and immediately centrifuged at 5000 rpm for 15 min. Plasma was 
stored at -80°C until analysis. 
2.5 Hepcidin, prohepcidin and inflammatory parameters 
Plasma hepcidin and prohepcidin concentrations were measured by enzyme-linked 
immunoassays using a commercially available kits (DRG Diagnostics, Marburg, Germany) in 
duplicates - the analytical sensitivity of the assay for hepcidin analysis was 0.9 ng/ml, intra-
assay coefficients of variation (CV) calculated by DRG Diagnostics was below 5%, inter-assay 
precision was 11% (6,0 ng/ml) and 10% (15,8 ng/ml). Plasma levels of procalcitonin (PCT) 
were detected by Kryptor test (BRAHMS AG, Hennigsdorf, Germany) in duplicates. The 
sensitivity of the analytic method was 0.02 ng/ml. Plasma concentrations of tumor necrosis 
factor (TNF)ǂ, IL-6, IL-8 (ELISA, Immunotech, Paris, France), C-reactive protein (CRP) 
(Kryptor - TRACE technology, ultrasensitive analysis, BRAHMS AG, Hennigsdorf, Germany), 
ǂ1-antitrypsin, and ceruloplasmin (nephelometry, BRAHMS AG, Hennigsdorf, Germany) 
were measured in duplicates, too. The intra- and inter-assay CV were below 5%. 
2.6 Iron, ferritin and transferrin 
Plasma iron (colorimetric analysis, Pliva-Lachema a.s., Brno, Czech Republic), ferritin, and 
transferrin (immunoturbidimetry, Dialab Gmbh, Wr. Neudorf, Austria) were examined 
preoperatively and repeatedly within 120 h after the end of surgery. 
2.7 Hemodynamic parameters 
Mean pulmonary artery pressure (MPAP), cardiac index (CI), pulmonary vascular resistance 
(PVR), and ejection fraction (EF) were followed. The time of norepinephrine support was 
recorded in all patients. 
2.8 Statistical analysis 
Statistical analysis was carried out using SPSS software (version 12.0) for Windows (SPSS, 
Chicago, USA). The normal distribution of all data was examined using the Kolmogorov-
Smirnov normality test to determine subsequent use of tests for statistical comparison. As 
variables were not normally distributed, the data were reported as medians and 
interquartile range. Bonferroni correction (multiple-comparison correction) was used to 
analyze simultaneous measurement at different time points. The Pearson’s correlation 
coefficient and the Spearman’s rank correlation evaluated correlation between the 
indicators. For all the tests, p < 0.05 was defined as statistically significant. 
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3. Results 
3.1 Patients 
34 patients were enrolled during the 39 months of the trial (Tab. 1). All patients underwent 
satisfactory clearance of intra-arterial obstruction, and there were no intra-operative deaths. 
No patients required allogenic blood transfusion. Mean duration of CPB was 334.2 ± 44.6 
min.; mean duration of crossclamping time was 121.0 ± 20.5 min. and circulatory arrest time 
41.9 ± 7.1 min. Extracorporeal circulation (ECC) time was 330.9 ± 54.4 min.; duration of 
mechanical ventilation was 51.9 ± 30.6 h. There was considerable improvement in 
hemodynamic variables. PEA significantly decreased MPAP (from 53.4 ± 8.66 to 25.1 ± 7.04 
mm Hg, p < 0.001) as well as pulmonary vascular resistance (from 1095.4 ± 325.3 to 209.7 ± 
94.1 dynes.s.cm-5, p < 0.001). CI increased within first 24 h after surgery (from 1.90 ± 0.37 to 
3.04 ± 0.49 l.min-¹m-², p < 0.001). 
 
Number of patients (males) 34 
Age (yr.) 51.4 (9.6) 
Preoperative New York Heart Association classification 3.4 (0.4) 
Mean pulmonary artery pressure (mm Hg) 54.2 (6.8) 
Variables are absolute number or mean (standard deviation). 
Table 1. Pre-operative data 
3.2 Prohepcidin 
The time course of prohepcidin in perioperative period is shown in Fig. 1. Cardiac surgery 
with CPB induced a 49 % fall in plasma prohepcidin. Prohepcidin decreased from 
preoperative level 94.9 ng/ml (84.5 – 104.9) (median and interquartile range) to minimum 48.5 
ng/ml (38.2 – 56.8). The initial decline was revealed after DHCA, and minimal concentrations 
 
 
 
Box and whisker plot depicting the median values, interquartile range and full range. 
 … Statistically significant differences to preoperative values, p  0.05.  
The same arrangement used for Fig 1 – 5. 
Fig. 1. Prohepcidin plasma concentrations in perioperative period. 
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were detected after separation from CPB (p  0.001 in relation to preoperative levels) after 
which the levels started rise. Concentrations returned to initial levels within 24 – 48 h after 
the separation from CPB. The following increase was found in samples at 72 h and 120 h, 
but without a statistical significance to preoperative levels on p  0.05. 
 
 
Fig. 2. Hepcidin plasma concentrations in perioperative period (median values, interquartile 
range and full range) 
3.3 Hepcidin 
Post-surgical course of plasma hepcidin was associated with a transient initial decline from 
preoperative level 8.6 ng/ml (6.4 – 10.2) and subsequent significant elevation above 
preoperative levels (Fig. 2). Minimal hepcidin concentrations were found in blood samples 
collected after the last DHCA. Initial decline of hepcidin appeared to correlate with the 
decreased hematocrit due to hemodilution on CPB (r = 0.86, p = 0.002). After it, hepcidin 
increased to maximum 16.2 ng/ml (13.9 – 18.9) measured 72 h after the end of surgery (e.g., 
separation from CPB). In following period, the levels started declining but were still higher 
than pre-operatively until 120 h after the end of surgery. 
3.4 Cytokines and acute-phase proteins 
As expected, all inflammatory cytokines, PCT and acute-phase proteins increased after 
surgery. An uncomplicated course after PEA was associated with a transient initial decline 
of PCT and subsequent elevation. Minimal PCT concentrations were found in blood samples 
collected after the last DHCA (Fig. 3). Initial decrease of PCT appeared to correlate with the 
decreased hematocrit due to hemodilution on CPB (r = 0.78, p < 0.01). PCT increased 
postoperatively from 0.22 ng/ml (0.15 – 0.31) reaching a peak level 24 h after the end of 
surgery (2.05 ng/ml, 1.68 – 2.52). 
All measured inflammatory cytokines increased after surgery. TNFǂ rose from 18 ng/l (10 – 
47) to maximum 216 ng/l (136 – 415) in blood sample collected 12 h after separation from 
CPB. IL-6 rise was maximal 12 hours postoperatively from 26.2 ng/l (21.0 – 36.7) to 544.2 
ng/l (411.0 – 641.2) with following decline (Fig. 4). IL-8 with preoperative levels 42.4 ng/l 
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(22.3 – 82.0) culminated later, 18 h after separation from CPB (446.0 ng/l, 274.2 – 658.1) with 
following decline. 
Three tested acute-phase proteins showed prolonged elevation post-surgery. CRP increased 
to a peak level 48 h after the end of surgery (53 mg/l, 40 – 72) (Fig. 5). The same dynamics 
was found in ǂ1-antitrypsin. Ceruloplasmin increase was delayed in relation to other tested 
acute-phase proteins reaching maximal levels 72 h after separation from CPB. 
3.5 Relations among hepcidin, prohepcidin and inflammatory markers 
Postoperative peak values of PCT and IL-6 correlated closely (r = 0.81, p < 0.01), as well as 
peak values of PCT and CRP (r = 0.72, p < 0.01) and peak values of PCT and TNFǂ (r = 0.62, 
p < 0.05). Correlation between PCT and other parameters wasn’t significant on p < 0.05. 
Maximum postoperative concentrations of IL-6 correlated with maximum IL-8 levels (r = 
0.81, p < 0.01). 
Plasma hepcidin and prohepcidin concentrations didn’t correlate preoperatively. 
Correlation between maximum postoperative hepcidin concentrations 72 h after the end of 
surgery and prohepcidin concentrations at the same samples (p = 0.056) didn’t achieve 
statistical significance. 
No significant correlation was revealed between plasma hepcidin and IL-6 concentrations 
preoperatively as well as between hepcidin and other tested inflammatory markers, 
hemodynamic values, plasma iron, transferrin and ferritin before the start of surgery. 
Similarly plasma prohepcidin did not correlate with any tested inflammatory parameter, 
plasma iron, transferrin or ferritin preoperatively. 
Maximum post-operative concentrations of hepcidin measured 72 h after a separation from 
CPB correlated with maximum IL-6 levels 12 h after the end of surgery (r = 0.714, p = 0.021) 
as well as with IL-6 levels measured 18 h (r = 0.644, p = 0.032) and 24 h after the end of 
surgery (r = 0.614. p = 0.042). Similarly hepcidin and CRP concentrations correlated 
significantly 72 h after the end of surgery (p = 0.044). No other tested inflammatory 
parameter correlated with hepcidin post-surgery on p < 0.05. 
 
 
Fig. 3. PCT plasma concentrations in perioperative period (median values, interquartile 
range and full range) 
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Fig. 4. IL-6 plasma concentrations in perioperative period (median values, interquartile 
range and full range) 
 
 
Fig. 5. CRP plasma concentrations in perioperative period (median values, interquartile 
range and full range) 
3.6 Relations among hepcidin, prohepcidin and hemodynamic parameters 
Minimal perioperative prohepcidin concentrations correlated inversely with ECC time  
(r = -0.84, p < 0.01). When evaluating patients with a quick normalization of prohepcidin 
into preoperative range within 24 h after separation from CPB (Subgroup 1, n = 16), higher 
peak plasma levels of IL-6 (620.9 ng/l, 484.2 – 782.0) were revealed in this subgroup 
compared with patients with delayed prohepcidin normalization (Subgroup 2, n = 18), their 
IL-6 peak levels were 438.2 ng/l (370.1 – 512.7), p  0.05 between subgroups. Similarly, IL-8 
peak postoperative concentrations were higher in Subgroup 1 in relation to Subgroup 2, but 
the differences were not significant on p  0.05. 
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Hepcidin maximum concentrations correlated positively with ECC time (p = 0.049). 
Hepcidin evolution post-surgery was not related to CI, MPAP, PVR and EF on p  0,05. 
Among inflammatory markers, IL-6 plasma concentrations correlated inversely with CI at 
the time of separation from CPB (k = -0.644, p = 0.029). Similarly IL-8 concentrations 
correlated significantly with CI at the same time (k = -0.636, p = 0.017). 
3.7 Iron, ferritin and transferrin 
48 h postoperatively, there was a significant decrease in serum iron concentration (Table 2). 
Plasma ferritin levels (44.6 μg/l, 19.4 – 72.9 preoperatively) increased slightly at 36 h after 
separation from CPB (139.2 μg/l, 44.9 – 172.9) and stayed elevated without significant 
dynamics until the end of tested period. Plasma ferritin did not significantly correlate with 
prohepcidin and hepcidin or any other tested inflammatory parameter. Multifactorial 
analysis did not reveal significant correlation between hepcidin and iron, resp. prohepcidin 
and iron within a 120-hour time frame after a separation from CPB. Similarly, both 
parameters did not correlate with plasma transferrin, hemoglobin concentration, alanine 
aminotransferase or aspartate aminotransferase activities post-surgery. No correlation was 
found between plasma hepcidin or prohepcidin levels and creatinine levels in postoperative 
period. 
 
Time Iron (μmol/l) Ferritin (μg/l) Transferrin (g/l) 
Before sternotomy 21.3 (13.2 – 27.7) 44.6 (19.4 – 72.9) 2.6 (1.8 – 3.2) 
12 h after separation from CPB 13.4 * (7.9 – 22.3) 38.9 * (20.4 – 69.0) 1.6 * (1.0 – 2.2) 
18 h after separation from CPB 13.7 * (7.1 – 18.5) 59.9 (28.4 – 88.2) 2.0 (1.4 – 2.6) 
24 h after separation from CPB 15.0 (9.6 – 20.7) 112.1 (69.4 – 164.3) 1.8 (1.3 – 2.3) 
36 h after separation from CPB 14.1 (9.8 – 19.8) 139.2 * (44.9 – 172.9) 1.6 * (1.0 – 2.1) 
48 h after separation from CPB 12.7 * (7.7 – 16.1) 128.0 * (74.7 – 188.3) 1.6 * (0.9 – 2.0) 
72 h after separation from CPB 13.0 * (7.0 – 18.8) 122.4 * (71.2 – 152.1) 2.1 (1.7 – 2.8) 
120 h after separation from CPB 12.4 * (7.4 – 19.1) 116.7 * (79.0 – 164.2) 2.3 (1.9 – 3.1) 
Variables are medians (interquartile range). 
* … Statistically significant differences to preoperative values on p  0,05. 
Table 2. Plasma iron, ferritin and transferrin in perioperative period 
4. Discussion 
This study has demonstrated the large cardiac surgery as an inductor of a deep transient 
decrease of prohepcidin plasma concentrations. Minimal postoperative prohepcidin levels 
were related to ECC time and did not correlate with IL-6 or other tested inflammatory 
parameters. Nevertheless higher IL-6 concentrations advanced prohepcidin normalization 
after its initial decline. Postoperative changes of plasma iron or transferrin concentrations 
and hemoglobin concentration did not correlate with plasma prohepcidin levels. Hepcidin 
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concentrations increased post-operatively reaching a maximum 72 h after the separation 
from CPB. In a homogenous group of uncomplicated cardiosurgical patients, significant 
correlation between hepcidin and IL-6 concentrations post-surgery was observed. Our 
results are in conformity with a recent study by Hoppe et al. (2009). On a limited number of 
patients undergoing heart surgery, authors found significant alterations in both serum 
hepcidin and serum prohepcidin. Serum prohepcidin decreased after 48 h compared with 
preoperative values, whereas serum hepcidin increased within a 144-hour time frame. 
The human hepcidin gene, located on chromosome 19q13.1, encodes a precursor protein, 
preprohepcidin of 84 aa. Preprohepcidin undergoes enzymatic cleavage, resulting in the export 
of a 64 -aa prohepcidin peptide into the endoplasmic reticulum lumen. Next, the 39-aa pro-
region peptide is probably posttranslationally removed resulting in mature bioactive hepcidin-
25 (25-aa form). In human urine, hepcidin-22 and hepcidin-20 were identified, which are N-
terminally truncated isoforms of hepcidin-25 (Park et al., 2001). Kemna et al. (2008) results 
support the hypothesis that the 22-aa peptide is a urinary degradation product of hepcidin-25. 
An active hepcidin is a 8 cysteine-containing peptide with a distorted ǃ-sheet which is 
stabilized by four disulfide bridges between the two anti-parallel strands (Hunter et al., 2002). 
The high cysteine content of the molecule is highly conserved among other species. Structure-
function in vivo (mice) and in vitro studies on synthetic hepcidin have shown that the iron 
regulating bioactivity is almost exclusively due to the 25 aa peptide, suggesting that the five N-
terminal amino acids are essential for this activity. In vitro experiments have shown that 
especially human hepcidin-20 exerts anti-bacterial and anti-fungal activity in a concentration 
range 10-fold higher than that measured in healthy individuals (Krause et al., 2000; Park et al., 
2001). Nevertheless modeling of a best-fit 3D structure of hepcidin with iron demonstrated 
significant differences from the previously reported synthetic hepcidin model (Hunter et al., 
2002). These new findings suggest a conformational polymorphism for hepcidin as a 
regulatory mechanism for iron uptake as part of its role as regulator of iron homeostasis. 
Hepcidin is produced and secreted predominantly by hepatocytes, circulates in the 
bloodstream, and is excreted by the kidneys. Expression as studied on mRNA level is also 
detectable in other tissues (heart, kidney, adipose tissue, pancreas and hematopoietic cells), 
although the biological relevance of extra-hepatic hepcidin is not well defined yet (Vokurka 
et al., 2009). Hepcidin expression is regulated in response to iron, erythropoietic demand, 
hypoxia, and inflammatory signals. Inflammation is a potent inducer of hepcidin 
expression. Hepcidin was demonstrated to be up-regulated by a set of inflammatory 
cytokines. The synthesis is up-regulated in intact animals by the injection of 
lipopolysaccharide (endotoxin) and IL-6 although a direct stimulating effect of other 
cytokines as IL-1ǂ, and IL-1ǃ was confirmed in in vitro studies (Lee et al., 2005). Anemia and 
hypoxia inhibit hepcidin expression, thus increasing iron availability for erythropoiesis. 
Probably the activity of erythropoiesis rather than simple anemia was postulated later as an 
important regulatory factor (Vokurka et al., 2006; Weiss & Goodnough, 2005). Recent studies 
brought new data about molecular pathways of the regulation of hepcidin gene through 
these different stimuli (reviewed by Kemna et al., 2008; Zhang & Enns, 2009).  
In vitro observations and first animal and clinical studies including our results support a 
submission of hepcidin into a group of acute-phase proteins (Young et al., 2009). Acute-phase 
proteins is the generic name of approximately 30 different biochemically and functionally 
unrelated proteins. These proteins are secreted by hepatocytes and their plasma levels are 
either increased (positive reactants) or reduced (negative acute-phase reactants) after the onset 
of a systemic inflammatory reaction (Baumann, 1988). Cell types other than hepatocytes are 
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known to produce acute-phase proteins in a limited amount. Most of acute-phase proteins are 
glycoproteins (with exception of CRP and serum amyloid A). Actually about 20 cytokines are 
known to stimulate acute-phase protein synthesis in liver. The major inducers are IL-6, IL-1ǃ, 
and TNFǂ but an essential role of IL-6 in this action is out of doubt (Gabay & Kushner, 1999). 
Considering a dominant regulation by IL-6, hepcidin was classified as a type II acute-phase 
protein. Type I acute-phase proteins (CRP, serum amyloid A, ǂ1-acid glycoprotein and other) 
are those that require the synergistic action of IL-6 and IL-1ǃ for maximum synthesis. Type II 
acute-phase proteins are those that require IL-6 only for maximal induction. Examples of type 
II proteins are fibrinogen chains, haptoglobin, and ǂ2-macroglobulin. Expression of genes 
encoding type II acute-phase proteins is suppressed rather than being enhanced frequently by 
IL-1ǃ (Ramadori et al., 1999). Additive, synergistic, co-operative, and antagonistic effects 
between cytokines and other mediator substances influencing the expression of acute phase 
proteins do occur and have been observed in almost all combinations. 
There is a well-characterized mechanism of direct transcriptional activation of hepcidin 
expression by IL-6 binding to its receptor complex containing gp130 to activate janus kinase 
(JAK) and activator of transcription STAT3, which binds to a conserved DNA element in the 
proximal hepcidin promoter (Nemeth et al., 2003 and 2004; Pietrangelo et al., 2007; Truksa et 
al., 2007, Verga Falzacappa et al., 2007, Wrighting  Andrews, 2006). Other 
proinflammatory cytokines, such as IL-1ǃ, may also play a role in hepcidin induction (Lee et 
al., 2005). A second mode of hepcidin regulation depends upon signaling through the bone 
morphogenetic protein/Smad (BMP/Smad) pathway. Babitt et al. (2007) showed that mice 
with a deletion in the Smad4 gene were unable to synthesize hepcidin in response to 
inflammatory stimuli or to iron load. In means that induction by IL-6 appears to require an 
intact BMP/Smad signaling pathway. Hepcidin is also produced in mono-
cytes/macrophages, and is induced in these cells by LPS and certain bacterial pathogens 
through Toll-like receptors and possibly also the IL-6/STAT3 pathway (Liu et al., 2005). 
The dynamic of hepcidin precursor - prohepcidin was different from hepcidin and all tested 
inflammatory markers including PCT, cytokines and acute-phase proteins. Prohepcidin 
decreased post-operatively. The decrease of prohepcidin after a heart surgery was firstly 
documented by Hoppe et al. (2009). However there are some controversies between clinical 
findings and experimental studies. In a recent experimental lipopolysaccharide model, the 
investigators did not observe any change in serum prohepcidin during a shorter time frame 
of 22 h, although there was a tendency toward a decrease at the final observation (Kemta et 
al., 2005). There is a possibility that serum prohepcidin is a biological nonfunctional 
precursor of the active hepcidin, as was postulated by Taes et al. (2004) or Brookes et al. 
(2005). It has been demonstrated by Rivera et al. (2005) that the truncated 25-aa form of 
hepcidin exercises the hypoferremia effect. Furthermore, the same study assessed the 
relation between iron absorption and prohepcidin concentrations in healthy women and it 
did not see any correlation, Iron absorption by healthy women is not associated with either 
serum or urinary prohepcidin. Thus, a Hoppe’s interpretation of the present serum 
prohepcidin data showing a decrease following surgery is that serum prohepcidin (as 
insulin and proteases) is synthesized as an inactive precursor that is proteolytically trimmed 
to be activated (Hoppe et al., 2009). 
Technical problems complicated routine measurements of plasma hepcidin until 2009 
(Piperno et al., 2009). Substantial clinical results come from the measurement of prohepcidin 
but its relation to hepcidin remains unclear (Frazer & Anderson, 2009). Hepcidin was 
measured in serum or urine mainly by the method developed by Ganz (2008) and by 
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various modifications of mass spectrometry (Swinkels et al., 2008). Recent methods used for 
hepcidin measurement comprise mass spectrometry (SELDI-TOF MS, MALDI-TOF MS, LC-
MS/MS, IC-TOF-MS) and immunochemical assays (competitive ELISA or RIA). Mass 
spectrometry-based methods might be superior in detecting bioactive hepcidin-25 and dis-
tinguishing other isoforms. This may be valuable mainly in situations with variable presence 
of hepcidin isoforms like in chronic kidney disease (Kroot et al., 2009; Kroot et al., 2010). 
The initial decrease of hepcidin and inflammatory cytokines was explained by 
hemodilution. The effect of hemodilution and hemofiltration on cytokine and acute phase 
protein concentrations during PEA was well described in our previous study (Maruna et al., 
2008) and cleared after correction of cytokine concentrations to hematocrit. Other limitations 
of this study include possibility of hemolysis impacting the study findings. When using the 
CPB pump in cardiosurgical procedures taking several hours, there is a degree of 
mechanical hemolysis that can affect hematological biomarkers (Hoppe et al., 2009). 
5. Conclusion 
Our study showed prohepcidin as a negative acute phase reactant with a strong initial 
decrease after PEA. On the other hand, hepcidin increased after uncomplicated cardiac 
surgery and this finding is in conformity with recent experimental studies defining hepcidin 
as a type II acute-phase protein. Relations between IL-6 levels and duration of prohepcidin 
disturbance as well as between IL-6 and hepcidin post-surgery course were revealed in our 
study. It remains to be determined whether the initial decrease of prohepcidin documented 
in our study is due to proteolytic trimming of serum prohepcidin or there are another 
factors restraining prohepcidin elevation or inhibiting its production. 
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7. Abbreviations 
BMP Bone morphogenetic protein 
CPB Cardio-pulmonary bypass 
CRP C-reactive protein 
CTEPH Chronic thromboembolic pulmonary hypertension 
CV Coefficients of variation 
DHCA Deep hypothermic circulatory arrest 
ECC Extracorporeal circulation 
EF Ejection fraction 
IC-TOF-MS Immunocapture time-of-flight mass-spectrometry 
IL Interleukin 
LC-MS/MS Liquid chromatography tandem-MS techniques 
MALDI-TOF MS Matrix assisted laser desorption/ionization time-of-flight mass 
spectrometry 
MPAP Mean pulmonary artery pressure 
PCT Procalcitonin 
PEA Pulmonary endarterectomy 
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PVR Pulmonary vascular resistance 
SELDI-TOF MS Surface enhanced laser desorption/ionization time-of-flight mass 
spectrometry 
SPSS Statistical package for social sciences 
STAT 3 Signal transducer and activator of transcription 3 
TNFǂ Tumor necrosis factor-ǂ 
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